Tri-nymyo Kit
Product Images NDC 51862-646

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Tri-nymyo (NDC 51862-646). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mayne Pharma Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Image 01)

This is a set of instructions for administering Tri-Nymyo, a combination of contraceptive pills. The instructions include details on the color of the pills, when to start taking them based on current contraceptive use or menstrual cycle, and how to switch from another form of contraception. It is important to also consider the possibility of ovulation and conception prior to starting the product. The full instructions for proper tablet usage are located in the FDA-Approved Patient Labeling.*

FDA Label Image

2 (Image 02)

This text provides instructions on what to do if a Tri-Nymyo tablet is missed during the first three weeks of the pack. It includes instructions for if one or two tablets are missed, as well as what to do if three or more are missed in a row. It advises on the use of additional non-hormonal contraception if necessary.*

FDA Label Image

3 (Image 03)

FDA Label Image

4 (Image 04)

This is a table summarizing the pharmacokinetic parameters of norelgestromin, norgestrel, and ethinyl estradiol during a three-cycle study. The table lists the cycle day, Cmax (peak serum concentration), tmax (time to reach peak serum concentration), and AUCo-24n and % (area under serum concentration vs time curve from 0 to 24 hours) of NGMN, NG, and EE. SD (standard deviation) is also indicated. In some instances, the parameters were not calculated and are therefore designated as NC.*

FDA Label Image

5 (Image 05)

The table shows results from two multicenter, placebo-controlled trials for acne vulgaris indications after six months of treatment with norgestimate and ethinyl estradiol tri-cycle tablets, as well as placebo. The intent-to-treat population had statistically significant lesion reductions for both inflammatory and non-inflammatory lesions in the treatment group vs. placebo. Last Observation Carried Forward (LOCF) method was used.*

FDA Label Image

6 (Image 06)

FDA Label Image

7 (Image 07)

This text presents information about possible birth control methods for women, indicating the estimated number of pregnancies per 100 women in one year for each method. It includes hormonal options such as injections, pills, patches, vaginal rings, and intrauterine devices, as well as non-hormonal options such as diaphragms, condoms, and spermicides. The text advises avoiding sex during the most fertile days of the monthly cycle and emphasizes the option of sterilization as a permanent form of birth control. The last phrase suggests the brief possibility of not using birth control.*

FDA Label Image

8 (Image 08)

This is a table for a medication tracker with days of the week marked in columns and three colors: green, light blue, and white. The green and light blue are used to mark pill consumption for the week while white is left blank. The table is accompanied by the trademark, "Tri-Nymyo™" and instructions to take pills in a left to right order, marked by the days of the week.*

FDA Label Image

9 (Image 09)

This appears to be a set of instructions for taking birth control pills, with a section for "Day 1 Starters" and another for "Sunday Starters." It includes a diagram with different colored labels and instructs the user to take the pills in a specific direction each week.*

FDA Label Image

10 (Image 10)

FDA Label Image

11 (Image 11)

Tri-Nymyo is an oral contraceptive that comes in different dosage strengths (0.18mg/0.035mg, 0.215mg/0.035mg, and 0.25mg/0.035mg). It is manufactured by Mayne Pharma and intended to prevent pregnancy. It should not be used to protect against HIV or other sexually transmitted diseases.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.